|Assessment Status||Rapid Review Complete|
|Indication||As maintenance treatment of asthma in adults and adolescents 12 years and older not adequately controlled with inhaled corticosteroids and inhaled short acting β2 agonists.|
|Rapid review commissioned||13/05/2020|
|Rapid review completed||10/06/2020|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that Indacterol/mometasone furoate (Atectura®) be considered for reimbursement*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.